Milner Consortium reaches 10

Milner Consortium reaches 10

We are excited to announce that two new pharma partners — Eli Lilly and Company and Bristol Myers Squibb — have joined the Milner Consortium in the past month. Now with ten pharma partners and three academic partners, this has become one of the largest cross-sector...
Start Codon closes new £15 million venture fund

Start Codon closes new £15 million venture fund

Start Codon, the life science and healthcare business accelerator based in the Milner Therapeutics Institute, today announced that it has closed Start Codon Fund I LP (the “Fund”) at £15 million. The Fund will be used to support Start Codon’s offering to start-ups,...
OncoInnovation: TGIO 2020 Challenge winner

OncoInnovation: TGIO 2020 Challenge winner

Last month, the Translating Genomics in Oncology (TGIO) 2020 event was co-organized by two programmes of the CRUK Cambridge Centre – Early Detection and OncoInnovation  – together with the University Enterprise Zone. The OncoInnovation programme is delivered in the...
Kostas Tzelepis awarded John Goldman Fellowship

Kostas Tzelepis awarded John Goldman Fellowship

We are delighted to announce that Academic in Residence Kostas Tzelepis has been awarded a John Goldman Fellowship from Leukaemia UK to develop and characterize new drugs against the RNA methyltransferase METTL3, which he has previously uncovered as a relevant...
Kathryn Lilley awarded EMBO membership

Kathryn Lilley awarded EMBO membership

We are delighted to announce that Kathryn Lilley, Director of the Cambridge Centre for Proteomics, is among 63 leading scientists who have been awarded EMBO membership today – elected on the basis of their scientific excellence and pioneering research.  “The new...
Start Codon closes new £15 million venture fund

Start Codon announces first cohort of companies

Start Codon, the new healthcare accelerator based in the Milner Therapeutics Institute, today announced the first cohort of four companies who were enrolled in the programme this February and will debut at the Milner Symposium event this Friday June 26th and ONHelix...
Eisai join Milner Therapeutics Consortium

Eisai join Milner Therapeutics Consortium

We are delighted to announce that Eisai have joined the Milner Therapeutics Consortium, which now includes 8 pharma partners. Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan. Eisai’s corporate mission is defined...
Milner Consortium reaches 10

Providing COVID-19 support

Thank you to the numerous Milner affiliated companies who have been in contact to offer support  to the University and NHS at this time. Help tackle COVID-19 through research collaborations, by donating equipment or funding research The University of Cambridge is...
Milner Consortium reaches 10

Milner Institute closure for COVID-19

As part of the response to COVID-19 at the University of Cambridge, the Milner Therapeutics Institute will be closed for non-essential business from Friday March 20th until further notice. Events planned for March and April, including the Milner seminar series, have...
Welcome to the Tzelepis Group

Welcome to the Tzelepis Group

We are delighted that Dr Konstantinos Tzelepis has moved into the Milner Centre for Pathway Analysis as a new Academic in Residence. He brings significant expertise in the identification and characterisation of novel therapeutic targets using a wide range of applied...

Pin It on Pinterest